Personalized and targeted medicine for rare lung and other cancers SOMERVILLE, MA —December 6, 2022— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present its clinical strategy and results at the upcoming clinical trials in rare diseases conference. The Clinical Trials in Rare…

Read More

Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA —July 23, 2022— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present its technology for treating lung cancer patients at a therapeutics conference. The conference will focus on a diversity…

Read More

Targeted therapy for breast cancer is based on personalized medicine approach SOMERVILLE, MA — April 24, 2019— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th 2019. The presentation will address…

Read More

Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 26, 2018— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration…

Read More

Targeting Lung Cancer in Rare Disease Patient Populations SOMERVILLE, MA— June 19, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge ,…

Read More